COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01798628
Recruitment Status : Completed
First Posted : February 26, 2013
Last Update Posted : February 26, 2013
Sponsor:
Information provided by (Responsible Party):
Cougar Biotechnology, Inc.

Brief Summary:
The purpose of this study is to determine the effect of food on the pharmacokinetics (how the drug concentrations change over time) of abiraterone acetate 1000 mg when administered as a single dose in healthy male volunteers.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: Treatment A: abiraterone acetate Drug: Treatment B: abiraterone acetate Drug: Treatment C: abiraterone acetate Phase 1

Detailed Description:
This is an open-label (identity of assigned study drug will be known), randomized (treatment sequences will be assigned by chance) study of a single dose of abiraterone acetate 1000 mg administered orally (by mouth) in approximately 36 healthy male participants under fasted and fed conditions. Three doses of abiraterone acetate will be administered with a 7-day washout period between each dose. The total study duration for each participant will be 21 days. Participants will be randomized to one of six treatment sequences (ABC, ACB, BAC, BCA, CAB, CBA): Treatment A = abiraterone acetate 1000 mg administered after a high-fat meal; Treatment B = abiraterone acetate 1000 mg administered after a low-fat meal; Treatment C = abiraterone acetate 1000 mg administered in the fasted state. No food will be ingested for 4 hours post-dose. Participants will be confined at the clinical research unit from the day prior to dosing until clinic discharge on the day following dosing in each treatment period. Serial pharmacokinetic samples will be collected and safety will be monitored throughout the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Single Dose, Open-Label, Three-Period, Crossover Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Subjects
Study Start Date : September 2009
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Sequence ABC Drug: Treatment A: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal

Drug: Treatment B: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal

Drug: Treatment C: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state

Experimental: Sequence ACB Drug: Treatment A: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal

Drug: Treatment B: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal

Drug: Treatment C: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state

Experimental: Sequence BAC Drug: Treatment A: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal

Drug: Treatment B: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal

Drug: Treatment C: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state

Experimental: Sequence BCA Drug: Treatment A: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal

Drug: Treatment B: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal

Drug: Treatment C: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state

Experimental: Sequence CAB Drug: Treatment A: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal

Drug: Treatment B: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal

Drug: Treatment C: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state

Experimental: Sequence CBA Drug: Treatment A: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal

Drug: Treatment B: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal

Drug: Treatment C: abiraterone acetate
1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state




Primary Outcome Measures :
  1. Maximum observed concentration of abiraterone [ Time Frame: Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose ]
  2. Time to maximum concentration of abiraterone [ Time Frame: Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose ]
  3. Area under the concentration-time curve from time 0 to the last measurable concentration of abiraterone [ Time Frame: Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose ]
  4. Area under the concentration-time curve extrapolated to infinity of abiraterone [ Time Frame: Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose ]
  5. Apparent plasma terminal elimination rate constant of abiraterone [ Time Frame: Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose ]
  6. Apparent terminal elimination half-life of abiraterone [ Time Frame: Within 1 hour prior to dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours post-dose ]

Secondary Outcome Measures :
  1. Number of participants affected by an adverse event [ Time Frame: Up to Day 21 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • In good general health as determined by no clinically significant findings on medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory measurements
  • Body mass index within 18 kg/m2 to 32 kg/m2, inclusive
  • Non-tobacco users
  • Clinical laboratory values within protocol-defined parameters
  • Negative hepatitis panel (including hepatitis B surface antigen [HBsAg] and hepatitis C virus antibody [anti-HCV]),and negative human immunodeficiency virus (HIV) antibody screens
  • Negative test for selected drugs of abuse
  • Agrees to protocol-defined use of effective contraception

Exclusion Criteria:

  • Significant history or manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological or psychiatric disorder, as determined by the Principal Investigator
  • History or presence of an abnormal electrocardiogram
  • History of stomach or intestinal surgery resection that would potentially alter absorption and/or excretion of orally administered drugs
  • Screening serum total testosterone of <200 ng/dL
  • History of hypersensitivity reaction to the study drug, related compounds or excipients used in the formulation
  • Receipt of an investigational drug within 5 half-lives or 30 days prior to Day -1, whichever is longer
  • Abnormal diet during the 30 days prior to Day 1
  • Donation of blood or significant loss of blood within 56 days or plasma within 14 days prior to Day -1
  • Planned donation of blood or plasma from Screening through Study Completion, Day 21
  • Receipt of blood products within 2 months prior to Day 1
  • History of protocol-defined alcohol abuse
  • Known or suspected use of illicit drugs within the last year
  • Use of any medication on a chronic basis
  • Use of any prescription medications/products or over-the-counter non-prescription preparations within 5 half-lives or 7 days prior to Day -1 unless deemed acceptable by the Sponsor
  • Consumption of alcohol-containing foods or beverages within 24 hours prior to the first Check-in (Day -1)
  • Unwillingness to abstain from alcohol consumption from Day -1 to Study Completion (Day21)
  • Consumption of caffeine-containing or grapefruit-containing foods or beverages within 72 hours prior to Day -1
  • Unwillingness to abstain from caffeine-containing or grapefruit-containing foods or beverages from Day -1 through Study Completion (Day21)
  • Presence of sexual dysfunction or any medical condition that would affect sexual function
  • Unwillingness to refrain from strenuous exercise from 48 hours prior to Day -1 and for the duration of the study
  • Presence of any condition that, in the opinion of the Investigator, would limit the participant's ability to complete and/or participate in this study
  • Unwillingness to refrain from using any tobacco or nicotine-containing products during screening and throughout the study to Study Completion (Day 21)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01798628


Sponsors and Collaborators
Cougar Biotechnology, Inc.
Investigators
Layout table for investigator information
Study Director: Cougar Biotechnology, Inc. Clinical Trial Cougar Biotechnology, Inc.
Layout table for additonal information
Responsible Party: Cougar Biotechnology, Inc.
ClinicalTrials.gov Identifier: NCT01798628    
Other Study ID Numbers: CR016960
COU-AA-009 ( Other Identifier: Cougar Biotechnology, Inc. )
First Posted: February 26, 2013    Key Record Dates
Last Update Posted: February 26, 2013
Last Verified: February 2013
Keywords provided by Cougar Biotechnology, Inc.:
Healthy volunteers
Abiraterone acetate
Pharmacokinetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Abiraterone Acetate
Antineoplastic Agents
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 Enzyme Inhibitors